Myriad Genetics Collaborates with MD Anderson Cancer Center to Employ MRD Testing Platform

02 Aug 2023


Myriad Genetics, a renowned company specializing in genetic testing and precision medicine, announced a collaborative agreement with the University of Texas MD Anderson Cancer Center. This partnership aims to support research efforts focused on metastatic renal cell carcinoma (RCC) treatment selection and response.

To achieve this, Myriad will provide its minimal residual disease (MRD) testing platform, which utilizes a high-definition assay capable of detecting circulating tumor DNA (ctDNA).

According to BIS Research Expert Revti Bhaskar, “The escalating prevalence of various cancers globally, such as leukemia, lymphoma, and solid tumors, has contributed to the growing demand for MRD testing. Healthcare providers and researchers recognize the clinical utility of MRD assessment in monitoring treatment response, predicting relapse, and guiding therapeutic interventions.”

Moreover, BIS Research Report highlights that the global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.

Click here to download a FREE sample.

Here’s the Story- 
The joint research project will be led by Dr. Chad Tang and Dr. Pavlos Msaouel at MD Anderson. They will explore the potential of Myriad's MRD testing platform as a non-invasive tool for informing treatment selection, surveillance, and assessing radiotherapy treatment response in individuals with metastatic renal cell carcinoma (RCC). 

Currently, there is a lack of available non-invasive testing platforms specifically designed for RCC. Moreover, MRD tests based on exome sequencing of the tumor may not encompass enough variants to ensure sufficient sensitivity. Consequently, the objective of this research collaboration is to evaluate whether a comprehensive genome-wide approach to MRD, facilitated by Myriad's platform, can benefit patients with RCC.
 


Moreover, Myriad claims that its MRD assay is expected to exhibit greater sensitivity in RCC due to its ability to track thousands of variants identified through whole-genome sequencing of the tumor. This MRD test enables the monitoring of ctDNA levels during both treatment and surveillance following diagnosis. 

Metastatic renal cell carcinoma is a highly aggressive type of kidney cancer that often presents significant challenges in terms of treatment selection and response monitoring. Therefore, the development of non-invasive testing platforms such as Myriad's MRD assay has the potential to advance and improve the field of RCC research and clinical care. By leveraging the power of whole-genome sequencing and a comprehensive approach to MRD assessment, researchers hope to gain valuable insights into the disease's progression and ultimately enhance patient outcomes.

Conclusion
Hospitals and specialty clinics are expected to adopt MRD testing assays such as those manufactured by Myriad Genetics at a rapid pace, leading to significant growth in the market. 

Moreover, as the field of MRD testing progresses and solidifies its significance in cancer management, it becomes imperative for market participants to emphasize innovation, standardization, and accessibility to fully leverage the promising prospects that await.

Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.

 
 
 
 

Twitter Feeds

 

OUR CLIENTS